Bryan Garnier - CARBIOS (ALCRB FP) CARBIOS: Everything going as planned | CORPORATE | EUR15,5(+164%)

Report

Bryan Garnier

Xavier Regnard

CARBIOS: Everything going as planned | CORPORATE | EUR15,5(+164%)

CARBIOS - CORPORATE | EUR15,5(+164%)
Everything going as planned

Financial results in line with expectations
Biodegradation: commercial deployment awaited for H1 2020
Enzymatic biorecycling: expected as of 2023
Carbiosâ€™ technology fits into the circular economy

27/09/2019 3 EN

Underlying

CARBIOS

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Xavier Regnard

Other Reports on these Companies

Bryan Garnier

CARBIOS: Collaboration with Indorama Ventures to build the first industrial unit | CORPORATE | EUR70 VS. EUR60 (+107%)

CARBIOS - CORPORATE | EUR70 VS. EUR60 (+107%) Collaboration with Indorama Ventures to build the first industrial unit Carbios announced a collaboration with Indorama Ventures for the construction of its first industrial unit (bigger than anticipated). This collaboration is a very good news, not only because it confirms the credibility and potential of Carbios’ technology but also because it could lead to future licensing deals with Indorama, the world’s largest PET producer. We increase our TP from EUR60 to EUR70.

February 24, 2022 February 24, 2022 1 EN

Bryan Garnier

CARBIOS - CORPORATE | EUR60(+51%) Two PET producers shortlisted. Carbios is about to accelerate its industrial development

CARBIOS - CORPORATE | EUR60(+51%) Two PET producers shortlisted. Carbios is about to accelerate its industrial development Entering the final stage of selection First results from the demo plant confirm the potential of the technology Positive newsflow over the coming weeks should revive the stock momentum Very positive stance confirmed. TP EUR60

January 19, 2022 January 19, 2022 1 EN

Bryan Garnier

CARBIOS - CORPORATE | EUR60(+61%) European funding to support the industrial deployment of the enzymatic PET recycling

CARBIOS - CORPORATE | EUR60(+61%) European funding to support the industrial deployment of the enzymatic PET recycling A new grant that confirms the high potential of Carbios’ technology We expect further positive newsflow in the next few weeks/months On track for a first industrial unit by end-2024 Still a lot of upside to capture. Target price confirmed : EUR60

November 26, 2021 November 26, 2021 4 EN

Fastned: H1 results, GM recovery, roll-out acceleration expected in H2

This morning, Fastned published its H1 2025 key metrics and number of operating stations. H1 sales came in at EUR54.3m (+44% YoY), implying revenue of EUR26.3m in Q2 2025 (-9% vs cons. at EUR28.9m) and pointing to an annual run-rate of at least EUR108m (vs cons. at EUR130.8m for FY25 and STFe EUR13

8h / 50m 8h / 50m 1 EN

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Avantium: financing package update

Yesterday, Avantium announced it had reached a conditional agreement with ABN AMRO, ASN, ING, Invest-NL and Rabobank to extend and amend its senior debt facility agreement, representing up to EUR125.1m as of December 2024. As such, (i) the remaining EUR14.1m debt commitment would be cancelled in ex

August 13, 2025 August 13, 2025 1 EN

Damien Choplain ... (+2)

Damien Choplain
Oscar Haffen Lamm

Valneva : Strong H1 - Key Lyme vaccine catalyst ahead in Q4

Valneva delivered a solid H1 and reaffirmed its 2025 guidance. The company’s cash position, standing at €161m, is sufficient to fund operations through 2027e, providing solid financial visibility. Looking ahead, the next key catalyst is the Phase III data readout for VLA15, Valneva’s Lyme disease v

August 12, 2025 August 12, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

CARBIOS: Everything going as planned | CORPORATE | EUR15,5(+164%)

CARBIOS: Collaboration with Indorama Ventures to build the first industrial unit | CORPORATE | EUR70 VS. EUR60 (+107%)

CARBIOS - CORPORATE | EUR60(+51%) Two PET producers shortlisted. Carbios is about to accelerate its industrial development

CARBIOS - CORPORATE | EUR60(+61%) European funding to support the industrial deployment of the enzymatic PET recycling

Fastned: H1 results, GM recovery, roll-out acceleration expected in H2

Avantium: financing package update

Valneva : Strong H1 - Key Lyme vaccine catalyst ahead in Q4

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe